Extemporaneous compounding practices at the Lagos University Teaching Hospital
Main Article Content
Abstract
Background: Extemporaneous compounded preparations are prepared in a Pharmacy in response to an immediate request by a prescriber, in limited quantities for an individual patient through a prescription.
Objective: To investigate and evaluate extemporaneous compounding practices in the Pharmacy units in Lagos University Teaching Hospital with a view to strengthening the professional roles and responsibilities of Pharmacists in optimizing patient care.
Methods: Retrospective study involving collection of data from relevant pharmacy units undertaking extemporaneous compounding for the period of one year (1st January - 31st December, 2021). Information on all compounded products were collected on site and retrieved from compounding log books. The facilities used for compounding, documentation process and standard operating procedures were examined. Data were recorded and transferred to Microsoft excel 2003 for statistical analysis and calculation of descriptive statistics. Ethical approval was obtained from LUTH Health Research ethics committee.
Results: The study revealed a prevalence of extemporaneous compounding of 4.38 % of the total number of prescriptions and an average number of products compounded per month of 244.41 (95 % CI = 222.56 - 266.66). 85 drugs were compounded out of which 34 accounted for 95% of compounding activities. Suspensions were the most frequently compounded. Prevalence of medication error was found to be 2.01 %.
Conclusion: Although licensed medicines represent the gold standard for quality, efficacy and safety, there is no licensed medicines which fully meet the clinical needs of a particular patient. Pharmacists would therefore continue to be required to prepare extemporaneous products.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Share
References
Chowdhury C, McLachnan AJ and Krass I (2012). Characterizing specialized compounding in community pharmacies. Research in Social and
Administrative Pharmacy, 8 (3) : 240 - 252.
Jackson M and Lowey A (2010). Handbook of extemporaneous preparations. Pharmaceutical press, London, U.K pp 3-8
Nahata C, Morosco S and Lequire E (2000). Development of two stable oral suspension of Levodopa - carbidopa for children with amblyopia.
Journal of Paediatric Opthalmology and strabismus, 37: 333 - 337.
Arghahowa SE, Egharevba JO and Okon F (2013). Patterns of extemporaneous prescriptions and preparations in tertiary health institutions: a five year assessment. International Journal of Pharmaceutical Compounding,17 (5): 432 - 435.
Nahata MC and Allen LV (2008). Extemporaneous drug formulations. Clinical Therapeutics,30 (11) : 2112 - 2119.
Brion F, Nunn AJ and Rieutord A (2003). Extemporaneous preparation of oral medicines for children in European hospitals. Acta Paediatrica, 92 :486 - 490.
McPherson TB and Fontane P (2010). Patient centered care in the community - basedcompounding practice setting. Journal of American
Pharmaceutical Association, 50: 37 - 44.
Kristina SA, Wiedyaningsih C, Widyakusuma NN, Aditama H (2017). Extemporaneous compounding practice by pharmacists: A systematic review. International Journal of Pharmacy and Pharmaceutical Sciences 9 (2) : 42 - 46.
Marshall I W and Daly MJ (1996). Risk management in hospital pharmacy. Pharmacy Management, 12 : 44-47
Falconer R and Steadman K J(2017). Extemporaneously compounded medicines. Australian Prescriber, 40 (1): 5- 8
US. FDA (2004). Limited FDA Survey of compounded drug products.
US Food and Drug Administration. Pharmacy compounding 2006. Limited FDA Survey of compounded Drug Products. http://www.fda.gov/drugs/guidance compliance regulatory information / pharmacy compounding/ucm 204237.htm.Accessed Sept 2012.
Draper R (2003). The toxic pharmacist. http //. www.nytimes. com. 2003 /6/08/magazine/the -toxicpharmacist.html
Pappas A, McPherson R and Stewart K (2002).Extemporaneous dispensing: whatever happened to it? A survey of Australian general practitioners. Journal of Pharmaceutical Research. 32: 310 - 314.
Allen LV (2005). Paediatric formulation initiatives (editorial). International Journal of Pharmaceutical Compounding, 9 : 410.
Kairuz T, Myftiu J, Svirskis D, Hasan F, Lal A, Patel R, Kumar K., Chhim S, Singh, R and Gary S (2007). Extemporaneous compounding in New Zealand hospitals. International Journal of Pharmacy Practice. 15: 129 -131.
Buurma H, de Smet PAGM, Van den Hoff OP, Sysling H, Storimans M, Egberts ACG. (2003). Frequency, nature and determinants of pharmacy
compounded medicines in Dutch community pharmacies. Pharmacy World and Science, 25; 290 - 297.
McPherson TB, Fontane PE, Jackson KD, Martin KS, Berry T, Chereson R et al (2006). Prevalence of compounding in independent community practice. Journal of American. Pharmaceutical Association. 46: 568 - 573.
Richey RH, Craig JV, Shah UU, Food JL, Barker CE, Peak M et al (2012). The manipulation of drugs to obtain the required dose: a systematic review. Journal of Advanced.Nursing, 68: 2103 - 2112.
Gudeman J, Jozwiakowski M, Chollet J and Randell M (2013). Potential risks of pharmacy compounding. Drugs in Research